Verrica Pharmaceuticals Inc. (VRCA) Stock Score, Valuation & Financial Research
Verrica Pharmaceuticals Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 23/100.
Quick answer for VRCA
Verrica Pharmaceuticals Inc. currently has a Wall Street Score of 23/100. The stored market price is $4.53. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Verrica Pharmaceuticals Inc. does
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agr
VRCA financial snapshot
- Wall Street Score:
- 23/100
- Current price:
- $4.53
- Market capitalization:
- $77.8M
- Revenue:
- $37.2M
- Net income:
- $-17.8M
- Free cash flow:
- $-17.6M
- Cash:
- $20.6M
- Total debt:
- $1.4M
- EPS:
- -1.68
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 31/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-17.6M, showing cash burn in the current stored period.
- The balance sheet shows $20.6M of cash versus $1.4M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research VRCA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.